Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Abstract : For this patient population, low dose metronomic cyclophosphamide prednisolone might be a viable alternative. Its convenient oral administration, low cost, and lack of toxicity justify further studies alone, or in combination with other agents in HRPC patients.
Type de document :
Article dans une revue
Anticancer Research, International Institute of Anticancer Research, 2010, 30 (10), pp.4317-23
http://www.hal.inserm.fr/inserm-00555027
Contributeur : Grégoire Mignot
<>
Soumis le : mercredi 12 janvier 2011 - 09:17:19
Dernière modification le : vendredi 8 juin 2018 - 14:50:12
Sylvain Ladoire, Jean-Christophe Eymard, Sylvie Zanetta, Grégoire Mignot, Etienne Martin, et al.. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.. Anticancer Research, International Institute of Anticancer Research, 2010, 30 (10), pp.4317-23. 〈inserm-00555027〉
